Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Clinical Features of Anthroponotic Cutaneous Leishmaniasis in a Major Focus, Southeastern Iran, 1994-2014.

Khosravi A, Sharifi I, Fekri A, Kermanizadeh A, Bamorovat M, Mostafavi M, Aflatoonian MR, Keyhani A.

Iran J Parasitol. 2017 Oct-Dec;12(4):544-553.

2.

Leishmaniasis in humans: drug or vaccine therapy?

Ghorbani M, Farhoudi R.

Drug Des Devel Ther. 2017 Dec 22;12:25-40. doi: 10.2147/DDDT.S146521. eCollection 2018. Review.

3.

An α-Gal-containing neoglycoprotein-based vaccine partially protects against murine cutaneous leishmaniasis caused by Leishmania major.

Iniguez E, Schocker NS, Subramaniam K, Portillo S, Montoya AL, Al-Salem WS, Torres CL, Rodriguez F, Moreira OC, Acosta-Serrano A, Michael K, Almeida IC, Maldonado RA.

PLoS Negl Trop Dis. 2017 Oct 25;11(10):e0006039. doi: 10.1371/journal.pntd.0006039. eCollection 2017 Oct.

5.

A Review of Impact of Bam Earthquake on Cutaneous Leishmaniasis and Status: Epidemic of Old Foci, Emergence of New Foci and Changes in Features of the Disease.

Aflatoonian MR, Sharifi I, Aflatoonian B, Shirzadi MR, Gouya MM, Kermanizadeh A.

J Arthropod Borne Dis. 2016 Jan 6;10(3):271-80. eCollection 2016 Sep. Review.

6.

Kinetoplastid Membrane Protein-11 as a Vaccine Candidate and a Virulence Factor in Leishmania.

de Mendonça SC, Cysne-Finkelstein L, Matos DC.

Front Immunol. 2015 Oct 13;6:524. doi: 10.3389/fimmu.2015.00524. eCollection 2015. Review.

7.

A comprehensive review of cutaneous leishmaniasis in kerman province, southeastern iran-narrative review article.

Sharifi I, Aflatoonian MR, Fekri AR, Hakimi Parizi M, Aghaei Afshar A, Khosravi A, Sharifi F, Aflatoonian B, Khamesipour A, Dowlati Y, Modabber F, Nadim A.

Iran J Public Health. 2015 Mar;44(3):299-307. Review.

8.

Evaluation of Alum-Naltrexone Adjuvant Activity, on Efficacy of Anti-Leishmania Immunization with Autoclaved Leishmania major (MRHO/IR/75/ER) Antigens in BALB/C Mice.

Mohammadzadeh Hajipirloo H, Bozorgomd A, Shahabi S, Hazrati Tappeh K, Karamati SA.

Iran J Parasitol. 2014 Sep;9(3):311-8.

9.

Vaccines to prevent leishmaniasis.

Kumar R, Engwerda C.

Clin Transl Immunology. 2014 Mar 14;3(3):e13. doi: 10.1038/cti.2014.4. eCollection 2014 Mar. Review.

10.

Sphingomyelin Liposomes Containing Soluble Leishmania major antigens Induced Strong Th2 Immune Response in BALB/c Mice.

Chavoshian O, Biari N, Badiee A, Khamesipour A, Abbasi A, Saberi Z, Jalali SA, Jaafari MR.

Iran J Basic Med Sci. 2013 Sep;16(9):965-72.

11.

Investigation of Double-Band Electrophoretic Pattern of ITS-rDNA Region in Iranian Isolates of Leishmania tropica.

Ghatee M, Sharifi I, Mirhendi H, Kanannejad Z, Hatam G.

Iran J Parasitol. 2013 Apr;8(2):264-72.

12.

A review of preventative methods against human leishmaniasis infection.

Stockdale L, Newton R.

PLoS Negl Trop Dis. 2013 Jun 20;7(6):e2278. doi: 10.1371/journal.pntd.0002278. Print 2013. Review.

13.

The emergence of anthroponotic cutaneous leishmaniasis following the earthquake in southern villages of bam district, southeastern iran, 2010.

Aflatoonian MR, Sharifi I, Poursmaelian S, Hakimi-Parizi M, Ziaali N.

J Arthropod Borne Dis. 2013 Jun 10;7(1):8-14. Print 2013.

14.

Development of Leishmania vaccines: predicting the future from past and present experience.

Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, Gicheru MM.

J Biomed Res. 2013 Mar;27(2):85-102. doi: 10.7555/JBR.27.20120064. Epub 2012 Sep 30.

15.

Comparison of in vivo Adjuvanticity of Liposomal PO CpG ODN with Liposomal PS CpG ODN: Soluble Leishmania Antigens as a Model.

Golali E, Jaafari MR, Khamesipour A, Abbasi A, Saberi Z, Badiee A.

Iran J Basic Med Sci. 2012 Sep;15(5):1032-45.

16.

Cytokine responses to novel antigens in an Indian population living in an area endemic for visceral leishmaniasis.

Singh OP, Stober CB, Singh AK, Blackwell JM, Sundar S.

PLoS Negl Trop Dis. 2012;6(10):e1874. doi: 10.1371/journal.pntd.0001874. Epub 2012 Oct 25.

17.

Cutaneous leishmaniasis in bam: a comparative evaluation of pre- and post-earthquake years (1999-2008).

Sharifi I, Nakhaei N, Aflatoonian M, Parizi MH, Fekri A, Safizadeh H, Shirzadi M, Gooya M, Khamesipour A, Nadim A.

Iran J Public Health. 2011;40(2):49-56. Epub 2011 Jun 30.

18.

Cytokine responses to novel antigens in a peri-urban population in Brazil exposed to Leishmania infantum chagasi.

Stober CB, Jeronimo SM, Pontes NN, Miller EN, Blackwell JM.

Am J Trop Med Hyg. 2012 Oct;87(4):663-70. doi: 10.4269/ajtmh.2012.12-0180. Epub 2012 Jul 23.

19.

Adjuvants for Leishmania vaccines: from models to clinical application.

Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG.

Front Immunol. 2012 Jun 11;3:144. doi: 10.3389/fimmu.2012.00144. eCollection 2012.

20.

Vaccine Development Against Leishmania donovani.

Das A, Ali N.

Front Immunol. 2012 May 15;3:99. doi: 10.3389/fimmu.2012.00099. eCollection 2012.

Supplemental Content

Support Center